Page 95 - 《中国药房》2023年24期

疗患者的预防性抗真菌作用[J]. 上海交通大学学报（医 European Organization for Research and Treatment of
学版），2022，42（6）：792-796. Cancer/Invasive Fungal Infections Cooperative Group and
JIN L，XU W B，YE C J，et al. Prophylactic antifungal ef‐ the National Institute of Allergy and Infectious Diseases
fect of posaconazole on patients with hematological malig‐ Mycoses Study Group（EORTC/MSG）Consensus Group
nant tumor undergoing chemotherapy[J]. J Shanghai Jiao [J]. Clin Infect Dis，2008，46（12）：1813-1821.
Tong Univ Med Sci，2022，42（6）：792-796. [14] SEGAL B H，HERBRECHT R，STEVENS D A，et al. De‐
[ 6 ] 张飞雨，张瑞霞，宋学武，等. 影响泊沙康唑血药浓度相 fining responses to therapy and study outcomes in clinical
关因素的研究进展[J]. 中国医院药学杂志，2021，41（9）： trials of invasive fungal diseases：Mycoses Study Group
971-976. and European Organization for Research and Treatment of
ZHANG F Y，ZHANG R X，SONG X W，et al. Research Cancer consensus criteria[J]. Clin Infect Dis，2008，47
progress of influencing factors for plasma concentration （5）：674-683.
of posaconazole[J]. Chin J Hosp Pharm，2021，41（9）： [15] SHEN Y，HUANG X J，WANG J X，et al. Posaconazole
971-976. vs. fluconazole as invasive fungal infection prophylaxis in
[ 7 ] 屈若尘，于静，王子阳，等 . 泊沙康唑联用 PPI 对恶性血 China：a multicenter，randomized，open-label study[J]. Int
液病患者血药浓度和侵袭性真菌感染的影响[J]. 中国药 J Clin Pharmacol Ther，2013，51（9）：738-745.
房，2023，34（10）：1237-1241. [16] CORNELY O A，MAERTENS J，WINSTON D J，et al.
QU R C，YU J，WANG Z Y，et al. Effect of posaconazole Posaconazole vs. fluconazole or itraconazole prophylaxis
combined with proton pump inhibitors on blood concentra‐ in patients with neutropenia[J]. N Engl J Med，2007，356
tions and invasive fungal infection in patients with malig‐ （4）：348-359.
nant hematological disorders[J]. China Pharm，2023，34 [17] DESPLANQUES P Y，BURLACU R，POINSIGNON V，
（10）：1237-1241. et al. Factors influencing posaconazole plasmatic concen‐
[ 8 ] VAN DER ELST K C，BROUWERS C H，VAN DEN trations in patients presenting with acute myeloid leukemia
HEUVEL E R，et al. Subtherapeutic posaconazole expo‐ [J]. Med Mal Infect，2014，44（4）：174-179.
sure and treatment outcome in patients with invasive fun‐ [18] JIA M M，ZHANG Q W，QIN Z F，et al. Deciphering the
gal disease[J]. Ther Drug Monit，2015，37（6）：766-771. relationship between the trough concentration of posaco-
[ 9 ] JOHN J，LOO A，MAZUR S，et al. Therapeutic drug nazole and its efficacy and safety in Chinese patients with
monitoring of systemic antifungal agents：a pragmatic ap‐ hematological disorders[J]. Front Pharmacol，2020，11：
proach for adult and pediatric patients[J]. Expert Opin 575463.
Drug Metab Toxicol，2019，15（11）：881-895. [19] MÄRTSON A G，VERINGA A，BAKKER M，et al.
[10] DOLTON M J，BRÜGGEMANN R J，BURGER D M，et Posaconazole trough concentrations are not influenced by
al. Understanding variability in posaconazole exposure inflammation：a prospective study[J]. Int J Antimicrob
using an integrated population pharmacokinetic analysis Agents，2019，53（3）：325-329.
[J]. Antimicrob Agents Chemother，2014，58（11）：6879- [20] VEHRESCHILD J J，MÜLLER C，FAROWSKI F，et al.
6885. Factors influencing the pharmacokinetics of prophylactic
[11] SHU Y S，SHI Y P，YANG Y L，et al. Progress of triazole posaconazole oral suspension in patients with acute mye-
antifungal agent posaconazole in individualized therapy loid leukemia or myelodysplastic syndrome[J]. Eur J Clin
[J]. J Clin Pharm Ther，2022，47（12）：1966-1981. Pharmacol，2012，68（6）：987-995.
[12] 国家药典委员会 . 中华人民共和国药典：四部[M].2020 [21] MICELI M H，PERISSINOTTI A J，KAUFFMAN C A，et
年版.北京：中国医药科技出版社，2020：466-472. al. Serum posaconazole levels among haematological can‐
National Pharmacopoeia Commission. Chinese pharmaco‐ cer patients taking extended release tablets is affected by
poeia：part Ⅳ[M]. 2020 Edition. Beijing：China Medical body weight and diarrhoea：single centre retrospective
Science Press，2020：466-472. analysis[J]. Mycoses，2015，58（7）：432-436.
[13] DE PAUW B，WALSH T J，DONNELLY J P，et al. Re‐ （收稿日期：2023-07-10 修回日期：2023-11-15）
vised definitions of invasive fungal disease from the （编辑：陈 宏）

中国药房 2023年第34卷第24期 China Pharmacy 2023 Vol. 34 No. 24 · 3029 ·